We have conducted extensive tests and market analyses on a range of FDA-approved drugs to determine their suitability for iontophoretic delivery. From this analysis, we have selected several therapeutic areas in which our technology may offer considerable therapeutic, economic or lifestyle advantages over existing methods of administration.

Topical Dermal Anesthesia

 
Home Company Technology Products Partnering Careers News
 
© 2003 Vyteris. All Rights Reserved.  
Migraine Parkinson's Disease Topical Dermal Anesthesia